CNTG

SVB Securities analyst Puneet Souda maintained a Buy rating on Centogene NV (CNTG – Research Report) on July 15 and set a price target of $6.00. The company's shares closed last Tuesday at $2.13, close to its 52-week low of $1.83. According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -11.0% and a 35.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. Currently, the analyst consensus on Centogene NV is a Moderate Buy with an average price target of $6.00.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-its-buy-rating-for-centogene-nv-cntg?utm_source=advfn.com&utm_medium=referral